

Treatment Timeline




Figure S1: Treatment timeline. GPS, galinpepimut-S; GM-CSF, granulocyte-macrophage colony-stimulating factor




Figure S2: Summary of CD4+ cell subpopulation frequencies over time

GzB, Granzyme B






Figure S3: Summary of CD8+ cell subpopulation frequencies

GzB, Granzyme B


a.



b.



c.



d.




Figure S4: Cytokine responses of CD4 T cells to test peptides. (a) CD4 immune response against 122A in non-HLA2 patients (IL-2); (b) CD4 immune response against 122A1 in non-HLA2 patients (IL-2); (c) CD4 immune response against 427L in non-HLA2 patients (IL-2); (d) CD4 immune response against 331L in non-HLA2 patients (IL-2)

HLA, human leukocyte antigen; IL-2, interleukin 2









Figure S5: Cytokine responses of CD4 T cells to test peptides. (a) CD4 immune response against 122A in non-HLA2 patients (IFN γ); (b) CD4 immune response against 122A1 in non-HLA2 patients (IFN γ); (c) CD4 immune response against 427L in non-HLA2 patients (IFN γ); (d) CD4 immune response against 331L in non-HLA2 patients (IFN γ)

HLA, human leukocyte antigen; IFN γ , interferon gamma


a.



b.



c.



d.






Figure S6: Cytokine responses of CD8 T cells to test peptides. (a) CD8 immune response against 122A in non-HLA2 patients (TNF α); (b) CD8 immune response against 122A1 in non-HLA2 patients (TNF α); (c) CD8 immune response against 427L in non-HLA2 patients (TNF α); (d) CD8 immune response against 331L in non-HLA2 patients (TNF α)

HLA, human leukocyte antigen; TNF, tumor necrosis factor


a.



b.



c.



d.






Figure S7: Cytokine responses of CD8 T cells to test peptides. (a) CD8 immune response against 122A in non-HLA2 patients (IL-2); (b) CD8 immune response against 122A1 in non-HLA2 patients (IL-2); (c) CD8 immune response against 427L in non-HLA2 patients (IL-2); (d) CD8 immune response against 331L in non-HLA2 patients (IL-2)

HLA, human leukocyte antigen; IL-2, interleukin 2


a.



b.



c.



d.




Figure S8: Cytokine responses of CD8 T cells to test peptides. (a) CD8 immune response against 122A in non-HLA2 patients (IFN γ); (b) CD8 immune response against 122A1 in non-HLA2 patients (IFN γ); (c) CD8 immune response against 427L in non-HLA2 patients (IFN γ); (d) CD8 immune response against 331L in non-HLA2 patients (IFN γ)

HLA, human leukocyte antigen; IFN γ , interferon gamma




Figure S9: CA-125 responses

Table S1: HLA typing results

Study ID	A	B	C	DRB1	DQB1
1	02:01 30:01	41:01 45:01	17:MN 16:01	04:03 07:01	03:05 03:03
2	01:01 01:01	08:01 37:01	07:AJKDW 06:DDAR	03:01 10:01	02:01 05:01
3	24:02 31:01	35:08 38:01	04:AMEKR 12:AJUHH	11:01 14:04	03:01 05:03
5	23:AFCTD 25:01	18:RRG 49:01	12:AJUHH 07:AJKDW	15:01 16:01	06:02 05:02
6	11:01 33:03	15:01 44:03	14:03 04:AMEKR	04:06 13:02	03:02 06:04
7	03:01 03:01	08:01 35:01	07:01 04:01	01:01 03:01	05:01 02:01
8	02:01 30:02	15:10 42:01	03:04 17:01	13:03 14:54	03:01 05:03
9	02:01 32:01	14:01 35:08	08:02 04:01	07:01 11:04	02:02 03:01
10	01:01 01:01	35:02 52:01	06:02 12:02	11:04 15:02	03:01 06:01
11	24:02 24:02	27:05 35:02	07:01 04:01	11:04 14:54	03:01 05:03
12	02:01 11:01	44:03 52:01	16:01 12:02	07:01 15:AMKZA	02:02 06:01